Ildiko Mesteri

Dr. Ildiko Mesteri

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MSMartin Schepelmann
Martin Schepelmann
NKNadja Kupper
Nadja Kupper
VGValeriya Gushchina
Valeriya Gushchina
IMIldiko Mesteri
Ildiko Mesteri
TMTeresa Manhardt
Teresa Manhardt
Enikö KállayEnikö Kállay
Enikö Kállay
Colitis is a major risk factor for the development of colorectal cancer, leading to colitis-associated colorectal cancer (CAC). The most commonly used animal model to study CAC is the azoxymethane-dextran sulphate-sodium (AOM/DSS) model. The ideal experimental conditions of this model depend on several factors, including the used mouse strain. No data on feasibility and conditions for older mice, e.g., for aging studies, have yet been reported. Thus, we conducted a descriptive, observational pilot study where CAC was induced in 14-month-old female Balb/C and C57/Bl6 mice using 12.5 mg/kg AOM i.p. and three different concentrations of DSS (1, 2, and 3%) in drinking water (ad. lib.). The mice were monitored regularly during the three-month experimental phase. After euthanasia, the colons of the mice were evaluated macroscopically and microscopically. Both the mouse strains showed a DSS-concentration-dependent induction of CAC. Carcinomas were only observed at 3% DSS. The DSS dose was found to be significantly correlated with the histology score and % Ki67 positive cells only in C57/Bl6 mice but not in Balb/C mice, which showed a variable response to the CAC induction. No differences in colon length, weight, or mucin content were observed. Optimal conditions for CAC induction in these aged animals are thus considered to be 3% DSS, as carcinomas did not develop when 2% DSS was used. On the other hand, Balb/C mice reacted severely to 3% DSS, indicating that 2.5% DSS may be the “sweet spot” for future experiments comparing CAC in aged Balb/C and C57/Bl6 mice. This model will allow investigation of the effect of aging on CAC development and therapy.

16 December 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
TETaha Elajnaf
Taha Elajnaf
LIluca iamartino
luca iamartino
IMIldiko Mesteri
Ildiko Mesteri
CMChristian Müller
Christian Müller
MBMarcella Bassetto
Marcella Bassetto
MSMartin Schepelmann
Martin Schepelmann
The calcium-sensing receptor (CaSR) is the main regulator of extracellular Ca2+ homeostasis. It has diverse functions in different tissues, including the intestines. Intestine-specific knockout of the CaSR renders mice more susceptible to dextran sulphate sodium (DSS)-induced colitis. To test our hypothesis that the CaSR reduces intestinal inflammation, we assessed the effects of nutritional and pharmacological agonists of the CaSR in a colitis model. We treated female Balb/C mice with dietary calcium and protein (nutritional agonists of the CaSR) or pharmacological CaSR modulators (the agonists cinacalcet and GSK3004774, and the antagonist NPS-2143; 10 mg/kg), then induced colitis with DSS. The high-protein diet had a strong pro-inflammatory effect—it shortened the colons (5.3 ± 0.1 cm vs. 6.1 ± 0.2 cm normal diet, p < 0.05), lowered mucin expression and upregulated pro-inflammatory cytokines, such as interferon-γ, (4.2-fold, p < 0.05) compared with the normal diet. Cinacalcet reduced mucin expression, which coincided with an increase in tumor necrosis factor-α (4.4-fold, p < 0.05) and IL-6 (4.9-fold, p < 0.05) in the plasma, compared with vehicle. The CaSR antagonist, NPS-2143, significantly reduced the cumulative inflammation score compared with the vehicle control (35.3 ± 19.1 vs. 21.9 ± 14.3 area under the curve, p < 0.05) and reduced infiltration of inflammatory cells. While dietary modulation of the CaSR had no beneficial effects, pharmacological inhibition of the CaSR may have the potential of a novel add-on therapy in the treatment of inflammatory bowel diseases.

23 December 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
CGCharlotte Gröschel
Charlotte Gröschel
MPMaximilian Prinz-Wohlgenannt
Maximilian Prinz-Wohlgenannt
IMIldiko Mesteri
Ildiko Mesteri
Sobha Karuthedom GeorgeSobha Karuthedom George
Sobha Karuthedom George
LTLena Trawnicek
Lena Trawnicek
Enikö KállayEnikö Kállay
Enikö Kállay
Inflammatory bowel disease increases the odds of developing colitis-associated cancer. We hypothesized that Western-style diet (WD) aggravates azoxymethane (AOM)/dextran sulfate sodium salt (DSS)-induced colitis-associated tumorigenesis and that switching to the standard AIN93G diet will ameliorate disease symptoms even after cancer initiation. Female BALB/c mice received either WD (WD group) or standard AIN93G diet (AIN group) for the whole experimental period. After five weeks, the mice received 12.5 mg/kg AOM intraperitoneally, followed by three DSS cycles. In one group of mice, the WD was switched to AIN93G the day before starting the first DSS cycle (WD/AIN group). Feeding the WD during the whole experimental period aggravated colitis symptoms, shortened the colon (p < 0.05), changed microbiota composition and increased tumor promotion. On molecular level, the WD reduced proliferation (p < 0.05) and increased expression of the vitamin D catabolizing enzyme Cyp24a1 (p < 0.001). The switch to the AIN93G diet ameliorated this effect, reflected by longer colons, fewer (p < 0.05) and smaller (p < 0.01) aberrant colonic crypt foci, comparable with the AIN group. Our results show that switching to a healthy diet, even after cancer initiation is able to revert the deleterious effect of the WD and could be an effective preventive strategy to reduce colitis symptoms and prevent tumorigenesis.

1 January 2021 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
AFAdrian Frick
Adrian Frick
VKVineeta Khare
Vineeta Khare
KJKristine Jimenez
Kristine Jimenez
KDKyle Dammann
Kyle Dammann
MLMichaela Lang
Michaela Lang
CGChristoph Gasche
Christoph Gasche
PAK1 belongs to a family of serine-threonine kinases and contributes to cellular pathways like NFκB, MAPK, PI3K/AKT and Wnt/ β-catenin all of which are involved in intestinal homeostasis. Overexpression of PAK1 is linked to IBD as well as colitis-associated cancer (CAC) and similar was observed in IL-10 KO mice, a model of colitis and CAC. Here we tested the effects of PAK1 deletion on intestinal inflammation and carcinogenesis in IL-10 KO mice. IL-10/PAK1 double knockout mice (DKO) were generated and development of colitis and CAC was analyzed. Large intestines were measured and prepared for histology or RNA isolation. Swiss rolls were stained with H&E and PAS. Co-immunoprecipitation and immunofluorescence were performed using intestinal organoids, SW480 and normal human colon epithelial cells (HCEC-1CT). When compared to IL-10 KO mice, DKOs showed longer colons and prolonged crypts, despite having higher inflammation and numbers of dysplasia. Crypt hyper-proliferation was associated with Notch1 activation and diminished crypt differentiation, indicated by a reduction of goblet cells. Gene expression analysis indicated upregulation of the Notch1 target HES1 and the stem cell receptor LGR5 in DKO mice. Interestingly, the stem cell marker OLFM4 was present in colonic tissue. Increased β-catenin mRNA and cytoplasmic accumulation indicated an aberrant Wnt-signaling. A co-localization and direct interaction of Notch1 and PAK1 was found in colon epithelial cells. Notch1 activation abrogated this effect whereas silencing of PAK1 led to Notch1 activation. PAK1 contributes to the regulation of crypt homeostasis under inflammatory conditions by controlling Notch1. This identifies a novel PAK1-Notch1 axis in intestinal pathophysiology of IBD and CAC.

1 August 2012 in Thrombosis Research
Verified
Journal Article
Closed access
JSJolanta M. Siller-Matula
Jolanta M. Siller-Matula
Ingrid MillerIngrid Miller
Ingrid Miller
MGManfred Gemeiner
Manfred Gemeiner
Roberto PlasenzottiRoberto Plasenzotti
Roberto Plasenzotti
GBGuenther Bayer
Guenther Bayer
BJBernd Jilma
Bernd Jilma

1 July 2015 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
WEW. Eigner
W. Eigner
IMIldiko Mesteri
Ildiko Mesteri
BTB. Tribl
B. Tribl
ABA. Ba-Ssalamah
A. Ba-Ssalamah
JFJ. Friedl
J. Friedl
LKL. Kazemi-Shirazi
L. Kazemi-Shirazi